Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection…
<!-- Name:DistributionId Value:8753188 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Aileron Therapeutics
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers…
p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia…
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg…
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to…
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical…
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia…
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save…
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data…
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate proof of principle that ALRN-6924 can…
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member…
BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who…
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming…
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for…
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study…
Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in…